© 2023 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
November 10, 2022
Closing out their discussion, Drs Hetty Carraway and Eytan M. Stein highlight an ongoing clinical trial investigating a triplet therapy for AML.
Dr Stein explains clinical trial data on the use of magrolimab plus azacitidine for patients with TP53-mutated AML.
November 04, 2022
Dr Carraway highlights some of the most urgent unmet needs for patients with higher-risk MDS.
Eytan M. Stein, MD, discusses how to treat patients with MDS who have IDH or TP53 mutations, and whether there is a role for targeted therapy in this patient population.
October 27, 2022
Dr Hetty Carraway muses on whether magrolimab plus azacitadine will be used as a standard treatment for higher-risk MDS in the future.
Drs Stein and Carraway explain the rationale for a magrolimab and azacitidine combination treatment for patients with higher-risk MDS with supporting data from 2 clinical trials.